Summary
- Current Price
- As of today, KRYS price is $348.09, down -0.90% on
- Current Price All-Time High
- KRYS price is currently -9.00% below its historical high of $382.54 set on
- Market Cap
- KRYS current market cap is $10B, up +159.11% over the past 365 days
- PE Ratio
- KRYS current PE ratio is 43.62
- Revenue
- KRYS current annual revenue is $389.13M, up +33.94% year-over-year
- Next Earnings
- The next earnings release for KRYS is on
Profile
| Metric | Value |
|---|---|
| Full Name | Krystal Biotech, Inc. |
| Ticker | NASDAQ: KRYS |
| Exchange | NASDAQ |
| Sector | Healthcare |
| Industry | Biotechnology |
| Country | United States |
| IPO | |
| Indexes | Not included |
| Website | krystalbio.com |
| Employees | 275 |
Key Metrics
| Metric | Value | Date |
|---|---|---|
| Price | $348.09 | |
| Price, 1D Change | -0.90% | |
| Market Cap | $10B | |
| - | ||
| PE Ratio | 43.62 | |
| Beta | 0.82 | |
| Revenue | $389.13M | |
| Revenue, 1Y Change | +33.94% | |
| EPS | $6.84 | |
| EPS, 1Y Change | +128.12% |
Chart
SUGGESTED SERIES
Events
| Metric | Value | Date |
|---|---|---|
| Next Earnings | ||
| Last Qtr. Earnings | ||
| Last Ann. Earnings | ||
| Last Ex-Dividend | N/A | N/A |
| Next Ex-Dividend | N/A | N/A |
| Last Split | N/A | N/A |
| Next Split | N/A | N/A |
| Last Ticker Change | N/A | N/A |
| Next Ticker Change | N/A | N/A |
🔒 Log In To Unlock Full Data
Estimates
| Metric | Value | Date |
|---|---|---|
| EPS | $6.84 | |
| EPS Estimate | $7.87 | N/A |
| EPS Est. Change | +15.01% | N/A |
| Revenue | $389.13M | |
| Revenue Estimate | $512.61M | N/A |
| Revenue Est. Change | +31.73% | N/A |
| Current Price | $348.09 | |
| Price Target | $389.00 | - |
| Price Tgt. Change | +11.75% | - |
🔒 Log In To Unlock Full Data
EPS
| Year | Estimate | Reported | Surprise / Exp. |
|---|---|---|---|
| $5.17 | $3.00 | -42.02% | |
| $7.13 | $6.84 | -4.06% | |
| $7.87 | N/A | +15.01% | |
| $9.40 | N/A | +37.42% |
Revenue
| Year | Estimate | Reported | Surprise / Exp. |
|---|---|---|---|
| $290.59M | $290.52M | -0.02% | |
| $387.60M | $389.13M | +0.39% | |
| $512.61M | N/A | +31.73% | |
| $654.56M | N/A | +68.21% |
🔒 Log In To Unlock Full Data
Performance
| Metric | Value | Date |
|---|---|---|
| Price, 1Y | +153.23% | |
| Price, 3Y | +180.63% | |
| Market Cap, 1Y | +159.11% | |
| Market Cap, 3Y | +196.92% | |
| Revenue, 1Y | +33.94% | |
| Revenue, 3Y | +100.00% | |
| EPS, 1Y | +128.12% | |
| EPS, 3Y | +224.55% |
🔒 Log In To Unlock Full Data
Technicals
| Metric | Value | Date |
|---|---|---|
| Current Price | $348.09 | |
| SMA 200 | $291.78 | |
| SMA 50 | $348.74 | |
| EMA 200 | $293.47 | |
| EMA 50 | $343.35 | |
| MACD | $4.87 | |
| Beta | 0.82 | |
| ATR | $12.59 | |
| 14-Day RSI | 49.17 | |
| 10-Day Volatility | 29.10% |
Dividends
| Metric | Value | Date |
|---|---|---|
| - | N/A | |
| Upcoming | N/A | N/A |
| - | ||
| - | ||
| $0.00 | ||
| 0.00% |
🔒 Log In To Unlock Full Data
Income & Profitability
| Metric | Value | Date |
|---|---|---|
| Revenue | $389.13M | |
| EPS | $6.84 | |
| Gross Profit | $360.36M | |
| Gross Margin | 92.61% | |
| Operating Income | $161.30M | |
| Operating Margin | 41.45% | |
| Net Income | $204.83M | |
| Net Margin | 52.64% | |
| EBITDA | $167.85M |
🔒 Log In To Unlock Full Data
Financial Health
| Metric | Value | Date |
|---|---|---|
| Debt To Equity | 0.01 | |
| 9.95 | ||
| 9.56 | ||
| - | ||
| 6 | ||
| 55.66 |
Valuations
| Metric | Value | Date |
|---|---|---|
| PE Ratio | 43.62 | |
| 23.39 | ||
| 7.58 | ||
| 46.31 | ||
| - | N/A |
Balance Sheet
| Metric | Value | Date |
|---|---|---|
| Book Value | $1.22B | |
| $827.79M | ||
| $1.33B | ||
| $1.02B | ||
| $114.23M | ||
| $102.94M | ||
| Total Debt | $9.34M | |
| $1.77M | ||
| $3.24M |
Expenses
| Metric | Value | Date |
|---|---|---|
| $184.30M | ||
| $199.06M | ||
| $28.77M | ||
| $0.00 | ||
| $6.55M | ||
| $0.00 | ||
| -$15.36M |
Cash Flow
| Metric | Value | Date |
|---|---|---|
| $200.87M | ||
| -$58.42M | ||
| $8.71M | ||
| Capex | $11.95M | |
| $188.91M |
Recent analyst updates
| Metric | Value | Date |
|---|---|---|
| RBC Capital | ||
| Citigroup | → | |
| B of A Securities | → | |
| TD Cowen | → | |
| HC Wainwright & Co. | → | |
| HC Wainwright & Co. | → | |
| HC Wainwright & Co. | → | |
| HC Wainwright & Co. | → | |
| Evercore ISI Group | → | |
| Citigroup | → |
Analyst sentiment
Institutional ownership
No data
Screeners with KRYS
FAQ
- What is the ticker symbol for Krystal Biotech, Inc.?
- The ticker symbol for Krystal Biotech, Inc. is NASDAQ:KRYS
- Does Krystal Biotech, Inc. pay dividends?
- No, Krystal Biotech, Inc. does not pay dividends
- What sector is Krystal Biotech, Inc. in?
- Krystal Biotech, Inc. is in the Healthcare sector
- What industry is Krystal Biotech, Inc. in?
- Krystal Biotech, Inc. is in the Biotechnology industry
- What country is Krystal Biotech, Inc. based in?
- Krystal Biotech, Inc. is headquartered in United States
- When did Krystal Biotech, Inc. go public?
- Krystal Biotech, Inc. initial public offering (IPO) was on September 20, 2017
- Is Krystal Biotech, Inc. in the S&P 500?
- No, Krystal Biotech, Inc. is not included in the S&P 500 index
- Is Krystal Biotech, Inc. in the NASDAQ 100?
- No, Krystal Biotech, Inc. is not included in the NASDAQ 100 index
- Is Krystal Biotech, Inc. in the Dow Jones?
- No, Krystal Biotech, Inc. is not included in the Dow Jones index
- When was Krystal Biotech, Inc. last earnings report?
- Krystal Biotech, Inc.'s most recent earnings report was on August 3, 2026
- When does Krystal Biotech, Inc. report earnings?
- The next expected earnings date for Krystal Biotech, Inc. is November 2, 2026
Data Sources & References
- KRYS Official Website www.krystalbio.com
- Most Recent Annual Report (10-K) www.sec.gov/Archives/edgar/data/1711279/000171127926000016/0001711279-26-000016-index.htm
- KRYS Profile on Yahoo Finance finance.yahoo.com/quote/KRYS
- KRYS Profile on NASDAQ.com www.nasdaq.com/market-activity/stocks/krys
